{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:37:52Z","timestamp":1777628272584,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["PE-2013-02355126"],"award-info":[{"award-number":["PE-2013-02355126"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.neuropharm.2023.109642","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T11:40:29Z","timestamp":1688038829000},"page":"109642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Blunted type-5 metabotropic glutamate receptor-mediated polyphosphoinositide hydrolysis in two mouse models of monogenic autism"],"prefix":"10.1016","volume":"238","author":[{"given":"Luisa","family":"Di Menna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosamaria","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"D'Errico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana Paula","family":"Ginerete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6378-4795","authenticated-orcid":false,"given":"Agata","family":"Machaczka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmela Maria","family":"Bonaccorso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Arena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Spatuzza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Celli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Alborghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Ciocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Rita","family":"Zuena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarosaria","family":"Scioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferdinando","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Vincenza","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109642_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41467-017-01191-2","article-title":"Altered surface mGluR5 dynamics provoke synaptic NMDAR dysfunction and cognitive defects in Fmr1 knockout mice","volume":"8","author":"Aloisi","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1515\/tnsci-2022-0217","article-title":"Longitudinal PET studies of mGluR5 in FXS using an FMR1 knockout mouse model","volume":"13","author":"Afshar","year":"2022","journal-title":"Transl. Neurosci."},{"issue":"6155","key":"10.1016\/j.neuropharm.2023.109642_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/331440a0","article-title":"Lithium inhibits adrenergic and cholinergic increases in GTP binding in rat cortex","volume":"331","author":"Avissar","year":"1988","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.neuropharm.2023.109642_bib4","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","article-title":"The mGluR theory of fragile X mental retardation","volume":"27","author":"Bear","year":"2004","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35036035","article-title":"The versatility and universality of calcium signalling","volume":"1","author":"Berridge","year":"2000","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109642_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109642_bib7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","article-title":"Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice","volume":"76","author":"Bhattacharya","year":"2012","journal-title":"Neuron"},{"issue":"6622","key":"10.1016\/j.neuropharm.2023.109642_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/386284a0","article-title":"Homer: a protein that selectively binds metabotropic glutamate receptors","volume":"386","author":"Brakeman","year":"1997","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109642_bib9","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/brainsci10120899","article-title":"Reduced expression of cerebral metabotropic glutamate receptor subtype 5 in men with fragile X syndrome","volume":"10","author":"Bra\u0161i\u0107","year":"2020","journal-title":"Brain Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109642_bib10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3390\/brainsci12030314","article-title":"Fragile X mental retardation protein and cerebral expression of metabotropic glutamate receptor subtype 5 in men with fragile X syndrome: a Pilot Study","volume":"12","author":"Bra\u0161i\u0107","year":"2022","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1460-9568.1997.tb01348.x","article-title":"Expression and coupling to polyphosphoinositide hydrolysis of group I metabotropic glutamate receptors in early postnatal and adult rat brain","volume":"9","author":"Casabona","year":"1997","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109642_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/hmg\/ddi077","article-title":"FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts","volume":"14","author":"Castets","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74848-6","article-title":"Chronic bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice","volume":"10","author":"Cogram","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109642_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.neubiorev.2014.02.003","article-title":"Dysregulation of group-I metabotropic glutamate (mGlu) receptor-mediated signaling in disorders associated with Intellectual Disability and Autism","volume":"46","author":"D'Antoni","year":"2014","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"8","key":"10.1016\/j.neuropharm.2023.109642_bib15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cells11081325","article-title":"Towards kinase inhibitor therapies for fragile X syndrome: tweaking twists in the autism spectrum kinase signaling network","volume":"11","author":"D'Incal","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s42003-020-0833-4","article-title":"Transcriptome signature analysis repurposes trifluoperazine for the treatment of fragile X syndrome in a mouse model","volume":"3","author":"Ding","year":"2020","journal-title":"Commun. Biol."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109642_bib17","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","article-title":"Correction of fragile X syndrome in mice","volume":"56","author":"D\u00f6len","year":"2007","journal-title":"Neuron"},{"issue":"39","key":"10.1016\/j.neuropharm.2023.109642_bib18","doi-asserted-by":"crossref","first-page":"8908","DOI":"10.1523\/JNEUROSCI.0932-05.2005","article-title":"A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome","volume":"25","author":"Giuffrida","year":"2005","journal-title":"J. Neurosci."},{"issue":"32","key":"10.1016\/j.neuropharm.2023.109642_bib19","doi-asserted-by":"crossref","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","article-title":"Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome","volume":"30","author":"Gross","year":"2010","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.neuropharm.2023.109642_bib20","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.celrep.2015.03.060","article-title":"Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome","volume":"11","author":"Gross","year":"2015","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109642_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41386-018-0150-5","article-title":"Isoform-selective phosphoinositide 3-kinase inhibition ameliorates a broad range of fragile X syndrome-associated deficits in a mouse model","volume":"44","author":"Gross","year":"2019","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109642_bib22","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1016\/j.celrep.2015.11.013","article-title":"Elevated CaMKII\u03b1 and hyperphosphorylation of homer mediate circuit dysfunction in a Fragile X syndrome mouse model","volume":"13","author":"Guo","year":"2015","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34978-4","article-title":"Mavoglurant in fragile X syndrome: results of two open-label, extension trials in adults and adolescents","volume":"8","author":"Hagerman","year":"2018","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109642_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neuron.2006.07.005","article-title":"Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression","volume":"51","author":"Hou","year":"2006","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.neuropharm.2023.109642_bib25","doi-asserted-by":"crossref","first-page":"R909","DOI":"10.1016\/j.cub.2018.07.046","article-title":"The mouse as a model for neuropsychiatric drug development","volume":"28","author":"Howe","year":"2018","journal-title":"Curr. Biol.: CB"},{"issue":"31","key":"10.1016\/j.neuropharm.2023.109642_bib26","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1523\/JNEUROSCI.1496-08.2008","article-title":"Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome","volume":"28","author":"Hu","year":"2008","journal-title":"J. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109642_bib27","doi-asserted-by":"crossref","first-page":"7746","DOI":"10.1073\/pnas.122205699","article-title":"Altered synaptic plasticity in a mouse model of fragile X mental retardation","volume":"99","author":"Huber","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.neuropharm.2023.109642_bib28","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1073\/pnas.0800257105","article-title":"Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome","volume":"105","author":"Kim","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.neuropharm.2023.109642_bib29","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1074\/jbc.M709585200","article-title":"Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt","volume":"283","author":"Kuo","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109642_bib30","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.nbd.2011.12.037","article-title":"Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome","volume":"45","author":"Liu","year":"2012","journal-title":"Neurobiol. Dis."},{"issue":"10","key":"10.1016\/j.neuropharm.2023.109642_bib31","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1523\/JNEUROSCI.4360-04.2005","article-title":"The scaffold protein Homer1b\/c links metabotropic glutamate receptor 5 to extracellular signal-regulated protein kinase cascades in neurons","volume":"25","author":"Mao","year":"2005","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","article-title":"Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice","volume":"74","author":"Michalon","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuropharm.2023.109642_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-94967-y","article-title":"In vivo imaging of mGlu5 receptor expression in humans with fragile X syndrome towards development of a potential biomarker","volume":"11","author":"Mody","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2023.109642_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1073\/pnas.83.6.1931","article-title":"Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoceptors","volume":"83","author":"Nicoletti","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7\u20138","key":"10.1016\/j.neuropharm.2023.109642_bib35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: from the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109642_bib36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neuropharm.2014.07.009","article-title":"Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2\/3 receptor agonists, LY379268 and LY354740","volume":"86","author":"Orlando","year":"2014","journal-title":"Neuropharmacology"},{"issue":"46","key":"10.1016\/j.neuropharm.2023.109642_bib37","doi-asserted-by":"crossref","first-page":"15616","DOI":"10.1523\/JNEUROSCI.3888-10.2010","article-title":"Hypersensitivity to mGluR5 and ERK1\/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome","volume":"30","author":"Osterweil","year":"2010","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.neuropharm.2023.109642_bib38","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1523\/JNEUROSCI.1846-13.2014","article-title":"Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling Angelman syndrome","volume":"34","author":"Pignatelli","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109642_bib39","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1124\/mol.110.067207","article-title":"Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity","volume":"78","author":"Rodriguez","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109642_bib40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1523\/JNEUROSCI.5019-07.2008","article-title":"Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation","volume":"28","author":"Ronesi","year":"2008","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109642_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/nn.3033","article-title":"Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome","volume":"15","author":"Ronesi","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109642_bib42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nn1134","article-title":"PI3 kinase enhancer-Homer complex couples mGluRI to PI3 kinase, preventing neuronal apoptosis","volume":"6","author":"Rong","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109642_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/npp.2014.245","article-title":"Relationship between in vivo receptor occupancy and efficacy of metabotropic glutamate receptor subtype 5 allosteric modulators with different in vitro binding profiles","volume":"40","author":"Rook","year":"2015","journal-title":"Neuropsychopharmacology"},{"issue":"41","key":"10.1016\/j.neuropharm.2023.109642_bib44","doi-asserted-by":"crossref","first-page":"E6290","DOI":"10.1073\/pnas.1610812113","article-title":"Elevated ERK\/p90 ribosomal S6 kinase activity underlies audiogenic seizure susceptibility in fragile X mice","volume":"113","author":"Sawicka","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109642_bib45","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuropharm.2016.07.001","article-title":"Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: implications for optimizing preclinical neuroscience drug discovery","volume":"115","author":"Sengmany","year":"2017","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2023.109642_bib46","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1523\/JNEUROSCI.3696-09.2010","article-title":"Dysregulation of mTOR signaling in fragile X syndrome","volume":"30","author":"Sharma","year":"2010","journal-title":"J. Neurosci."},{"issue":"30","key":"10.1016\/j.neuropharm.2023.109642_bib47","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.1523\/JNEUROSCI.1162-14.2014","article-title":"Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model","volume":"34","author":"Sidhu","year":"2014","journal-title":"J. Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2023.109642_bib48","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/j.celrep.2017.02.075","article-title":"\u03b2-arrestin2 couples metabotropic glutamate receptor 5 to neuronal protein synthesis and is a potential target to treat fragile X","volume":"18","author":"Stoppel","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.neuropharm.2023.109642_bib49","article-title":"mGluR5 negative modulators for fragile X: treatment resistance and persistence","volume":"12","author":"Stoppel","year":"2021","journal-title":"Front. Psychol."},{"issue":"47","key":"10.1016\/j.neuropharm.2023.109642_bib50","doi-asserted-by":"crossref","first-page":"11946","DOI":"10.1523\/JNEUROSCI.0672-16.2016","article-title":"Negative allosteric modulation of mGluR5 partially corrects pathophysiology in a mouse model of Rett syndrome","volume":"36","author":"Tao","year":"2016","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2023.109642_bib51","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/npp.2017.177","article-title":"Effect of the mGluR5-NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double-blind, placebo-controlled trial: FragXis phase 2 results","volume":"43","author":"Youssef","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109642_bib52","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3389\/fphar.2018.00804","article-title":"In vivo non-radioactive assessment of mGlu5 receptor-activated polyphosphoinositide hydrolysis in response to systemic administration of a positive allosteric modulator","volume":"9","author":"Zuena","year":"2018","journal-title":"Front. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823002320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T01:38:34Z","timestamp":1777426714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823002320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":52,"alternative-id":["S0028390823002320"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109642","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blunted type-5 metabotropic glutamate receptor-mediated polyphosphoinositide hydrolysis in two mouse models of monogenic autism","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109642"}}